
Enanta Pharmaceuticals Inc
ENTANASDAQ NMS - GLOBAL MARKETKey Statistics
Open
$13.19
Day High
$13.31
Day Low
$13.02
Prev. Close
$13.23
VolumeShares traded today.
174.75K
Avg. VolumeAverage daily volume.
—
Market CapTotal value of all shares = price × shares outstanding.
$382.67M
P/E (TTM)Price-to-Earnings: share price ÷ earnings per share over the last 12 months. Lower can mean cheaper; very high can mean growth expectations.
-5.07
Forward P/EP/E based on forecast next-year earnings.
—
P/B RatioPrice-to-Book: share price ÷ book value per share.
—
52W HighHighest price over the past 52 weeks.
$17.15
52W LowLowest price over the past 52 weeks.
$5.88
50D MAAverage closing price over the last 50 trading days.
$13.65
200D MAAverage closing price over the last 200 trading days.
$12.46
Dividend YieldAnnual dividend ÷ share price, as a %.
—
BetaVolatility vs the market. >1 = more volatile than the S&P 500.
—
Performance
1W
-4.8%1M
-5.1%6M
-3.7%YTD
-8.7%1Y
+121.9%About
Glecaprevir (INN,) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals. It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir. Together they demonstrated potent antiviral activity against major HCV genotypes and high barriers to resistance in vitro.
www.enanta.com/Company Facts
Similar stocks
Health CareSentiment
Latest News
Social Noise
Price Alerts
Loading…
Trade ENTA
Brokers available in your region (US)
Affiliate links — we may earn a commission. CFDs are risky.